Search results
Showing 16 to 30 of 32 results for prostatic hyperplasia
PLASMA system with button electrode for electrovaporisation of the prostate (MIB274)
NICE has developed a medtech innovation briefing (MIB) on PLASMA system with button electrode for electrovaporisation of the prostate .
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic...
and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic...
This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.
safety of insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic...
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia Number MTG58 Date issued May 2021 Other
Memokath-028, 044 and 045 stents for urethral obstruction (MIB123)
NICE has developed a medtech innovation briefing (MIB) on Memokath-028, 044 and 045 stents for urethral obstruction .
This advice has been updated and replaced by NICE medical technologies guidance 49.
Prostate artery embolisation for benign prostatic hyperplasia (IPG453)
This guidance has been updated and replaced by NICE interventional procedures guidance 611.
GreenLight XPS for treating benign prostatic hyperplasia (MTG29)
This guidance has been updated and replaced by NICE medical technologies guidance 74.
Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)
This evidence summary has been updated and replaced by NICE guideline CG97.
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG26)
This guidance has been updated and replaced by NICE medical technologies guidance 58.
This guidance has been updated and replaced by NICE interventional procedures guidance 737.